711 related articles for article (PubMed ID: 21907094)
1. Genetics and neuropathology of Huntington's disease.
Reiner A; Dragatsis I; Dietrich P
Int Rev Neurobiol; 2011; 98():325-72. PubMed ID: 21907094
[TBL] [Abstract][Full Text] [Related]
2. Autopsy-proven Huntington's disease with 29 trinucleotide repeats.
Kenney C; Powell S; Jankovic J
Mov Disord; 2007 Jan; 22(1):127-30. PubMed ID: 17115386
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of neuronal cell death in Huntington's disease.
Sawa A; Tomoda T; Bae BI
Cytogenet Genome Res; 2003; 100(1-4):287-95. PubMed ID: 14526190
[TBL] [Abstract][Full Text] [Related]
4. The use of transgenic and knock-in mice to study Huntington's disease.
Hickey MA; Chesselet MF
Cytogenet Genome Res; 2003; 100(1-4):276-86. PubMed ID: 14526189
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.
Rising AC; Xu J; Carlson A; Napoli VV; Denovan-Wright EM; Mandel RJ
Exp Neurol; 2011 Apr; 228(2):173-82. PubMed ID: 21192926
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic mechanisms in Huntington's disease.
Jones L; Hughes A
Int Rev Neurobiol; 2011; 98():373-418. PubMed ID: 21907095
[TBL] [Abstract][Full Text] [Related]
7. Towards a transgenic model of Huntington's disease in a non-human primate.
Yang SH; Cheng PH; Banta H; Piotrowska-Nitsche K; Yang JJ; Cheng EC; Snyder B; Larkin K; Liu J; Orkin J; Fang ZH; Smith Y; Bachevalier J; Zola SM; Li SH; Li XJ; Chan AW
Nature; 2008 Jun; 453(7197):921-4. PubMed ID: 18488016
[TBL] [Abstract][Full Text] [Related]
8. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
9. Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease.
Henley SM; Wild EJ; Hobbs NZ; Scahill RI; Ridgway GR; Macmanus DG; Barker RA; Fox NC; Tabrizi SJ
J Neurol; 2009 Feb; 256(2):203-12. PubMed ID: 19266143
[TBL] [Abstract][Full Text] [Related]
10. Huntington's disease: from pathology and genetics to potential therapies.
Imarisio S; Carmichael J; Korolchuk V; Chen CW; Saiki S; Rose C; Krishna G; Davies JE; Ttofi E; Underwood BR; Rubinsztein DC
Biochem J; 2008 Jun; 412(2):191-209. PubMed ID: 18466116
[TBL] [Abstract][Full Text] [Related]
11. A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease.
Aldous SG; Smith EJ; Landles C; Osborne GF; Cañibano-Pico M; Nita IM; Phillips J; Zhang Y; Jin B; Hirst MB; Benn CL; Bond BC; Edelmann W; Greene JR; Bates GP
Brain; 2024 May; 147(5):1784-1798. PubMed ID: 38387080
[TBL] [Abstract][Full Text] [Related]
12. Huntington's disease: clinical presentation and treatment.
Novak MJ; Tabrizi SJ
Int Rev Neurobiol; 2011; 98():297-323. PubMed ID: 21907093
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice.
Morton AJ; Glynn D; Leavens W; Zheng Z; Faull RL; Skepper JN; Wight JM
Neurobiol Dis; 2009 Mar; 33(3):331-41. PubMed ID: 19130884
[TBL] [Abstract][Full Text] [Related]
14. A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.
Cummings DM; Alaghband Y; Hickey MA; Joshi PR; Hong SC; Zhu C; Ando TK; André VM; Cepeda C; Watson JB; Levine MS
J Neurophysiol; 2012 Jan; 107(2):677-91. PubMed ID: 22072510
[TBL] [Abstract][Full Text] [Related]
15. Molecular aspects of Huntington's disease.
Walling HW; Baldassare JJ; Westfall TC
J Neurosci Res; 1998 Nov; 54(3):301-8. PubMed ID: 9819135
[TBL] [Abstract][Full Text] [Related]
16. Magnetization transfer imaging in 'premanifest' Huntington's disease.
Jurgens CK; Bos R; Luyendijk J; Witjes-Ané MN; van der Grond J; Middelkoop HA; Roos RA
J Neurol; 2010 Mar; 257(3):426-32. PubMed ID: 19823894
[TBL] [Abstract][Full Text] [Related]
17. Juvenile Huntington's disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease?
Squitieri F; Frati L; Ciarmiello A; Lastoria S; Quarrell O
Mech Ageing Dev; 2006 Feb; 127(2):208-12. PubMed ID: 16274727
[TBL] [Abstract][Full Text] [Related]
18. Uninterrupted CAG repeat drives striatum-selective transcriptionopathy and nuclear pathogenesis in human Huntingtin BAC mice.
Gu X; Richman J; Langfelder P; Wang N; Zhang S; Bañez-Coronel M; Wang HB; Yang L; Ramanathan L; Deng L; Park CS; Choi CR; Cantle JP; Gao F; Gray M; Coppola G; Bates GP; Ranum LPW; Horvath S; Colwell CS; Yang XW
Neuron; 2022 Apr; 110(7):1173-1192.e7. PubMed ID: 35114102
[TBL] [Abstract][Full Text] [Related]
19. Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice.
Lloret A; Dragileva E; Teed A; Espinola J; Fossale E; Gillis T; Lopez E; Myers RH; MacDonald ME; Wheeler VC
Hum Mol Genet; 2006 Jun; 15(12):2015-24. PubMed ID: 16687439
[TBL] [Abstract][Full Text] [Related]
20. Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies.
Jimenez-Sanchez M; Licitra F; Underwood BR; Rubinsztein DC
Cold Spring Harb Perspect Med; 2017 Jul; 7(7):. PubMed ID: 27940602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
